Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Genvoya · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Genvoya | EXPERIMENTAL | Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days |
| Name | Type | Description |
|---|---|---|
| Genvoya | DRUG | Oral use (one tablet each day); 150/150/200/10 mg; 28 days |
Inclusion Criteria: * an age above 18 years * consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) * indication for HIV post-exposure prophylaxis (according to French guidelines) * person able to understand the nature of the study * person who signed his conse...
Genvoya is a small molecule drug being studied for use in HIV risk, specifically as a post-exposure prophylaxis. It is currently in Phase 3 clinical development and is being developed by Gilead Sciences, Inc. The drug is intended for individuals at risk of HIV infection.
Genvoya is a small molecule drug being investigated for HIV post-exposure prophylaxis. It is being studied in a Phase 3 clinical trial to evaluate compliance with treatment in individuals at risk of HIV. The specific molecular target of Genvoya is not disclosed in the available information.
Genvoya is developed by Gilead Sciences, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 3 clinical development for use in HIV post-exposure prophylaxis.
Genvoya is in Phase 3 clinical development. It is being studied for use in HIV post-exposure prophylaxis, with a completed Phase 3 trial. Genvoya is an investigational drug and has not been approved by regulatory authorities for this indication.
Genvoya has one completed Phase 3 clinical trial, identified as NCT02998320, titled "Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis." The trial enrolled 101 participants in France, with a minimum age of 18 years, and included both male and female participants.
Genvoya is a drug developed by Gilead Sciences, Inc. for HIV post-exposure prophylaxis. No alternative names for Genvoya have been reported in the available information. It is being studied as a single agent in a Phase 3 clinical trial.